1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Kidney Disease - Drugs In Development, 2022, provides an overview of the Polycystic Kidney Disease (Genetic Disorders) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Polycystic kidney disease (PKD) is a disorder in which clusters of cysts develop primarily within kidneys. Polycystic kidney disease symptoms may include high blood pressure, back or side pain, headache, blood in urine, frequent urination and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs and diuretics.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Polycystic Kidney Disease - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Polycystic Kidney Disease (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Polycystic Kidney Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Polycystic Kidney Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 3, 18 and 14 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 2 molecules, respectively.
Polycystic Kidney Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Polycystic Kidney Disease (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Polycystic Kidney Disease (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Polycystic Kidney Disease (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Polycystic Kidney Disease (Genetic Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Polycystic Kidney Disease (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Polycystic Kidney Disease (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Polycystic Kidney Disease - Overview
- Polycystic Kidney Disease - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Polycystic Kidney Disease - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Polycystic Kidney Disease - Companies Involved in Therapeutics Development
- Polycystic Kidney Disease - Drug Profiles
- Polycystic Kidney Disease - Dormant Projects
- Polycystic Kidney Disease - Discontinued Products
- Polycystic Kidney Disease - Product Development Milestones
- Featured News & Press Releases
- Jul 13, 2022: XORTX announces positive topline results from pharmacokinetics bridging clinical trial
- Jul 07, 2022: XORTX announces pre-phase 3 meeting request with US Food and Drug Administration (FDA)
- Jun 21, 2022: Regulus Therapeutics announces receipt of FDA orphan drug designation for RGLS8429 for the treatment of autosomal dominant polycystic kidney disease (ADPKD)
- Jun 13, 2022: Regulus Therapeutics announces first subject dosed in phase 1 Single-Ascending Dose (SAD) Clinical Trial of RGLS8429 for the treatment of autosomal dominant polycystic kidney disease (ADPKD)
- May 11, 2022: Regulus Therapeutics announces FDA acceptance of Investigational New Drug (IND) application for RGLS8429 for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- May 05, 2022: XORTX opens an IND for XRx-008 program for Autosomal Dominant Polycystic Kidney Disease
- May 03, 2022: XORTX initiates dosing of human subjects in the XRX-OXY-101 clinical trial
- Apr 25, 2022: Poxel announces its participation in upcoming scientific conference of PXL770
- Apr 12, 2022: XORTX receives no objection letter from Health Canada
- Apr 07, 2022: XORTX announces grant of US patent
- Mar 31, 2022: XORTX files IND with US FDA
- Mar 14, 2022: XORTX Therapeutics announces submission of clinical trial application to conduct Bridging Pharmacokinetics Study
- Jan 20, 2022: Regulus Therapeutics announces successful completion of pre-IND meeting with FDA for RGLS8429
- Dec 21, 2021: XORTX Therapeutics announces filing of provision patent for polycystic kidney disease
- Dec 01, 2021: Regulus Therapeutics announces presentation at the first annual Rare & Genetic Kidney Disease Drug Development Summit
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Polycystic Kidney Disease, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Companies, 2022 (Contd..1)
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..1)
- Products under Development by Companies, 2022 (Contd..2)
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Target, 2022 (Contd..1)
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Polycystic Kidney Disease - Pipeline by AceLink Therapeutics Inc, 2022
- Polycystic Kidney Disease - Pipeline by Amathus Therapeutics Inc, 2022
- Polycystic Kidney Disease - Pipeline by AmMax Bio Inc, 2022
- Polycystic Kidney Disease - Pipeline by Angion Biomedica Corp, 2022
- Polycystic Kidney Disease - Pipeline by ATLAS Molecular Pharma SL, 2022
- Polycystic Kidney Disease - Pipeline by Bristol-Myers Squibb Co, 2022
- Polycystic Kidney Disease - Pipeline by Camurus AB, 2022
- Polycystic Kidney Disease - Pipeline by Centessa Pharmaceuticals Plc, 2022
- Polycystic Kidney Disease - Pipeline by Chimerna Therapeutics Inc, 2022
- Polycystic Kidney Disease - Pipeline by Chinook Therapeutics Inc, 2022
- Polycystic Kidney Disease - Pipeline by DiscoveryBiomed Inc, 2022
- Polycystic Kidney Disease - Pipeline by Eloxx Pharmaceuticals Inc, 2022
- Polycystic Kidney Disease - Pipeline by Galapagos NV, 2022
- Polycystic Kidney Disease - Pipeline by Generian Pharmaceuticals Inc, 2022
- Polycystic Kidney Disease - Pipeline by GLG Pharma SA, 2022
- Polycystic Kidney Disease - Pipeline by Goldfinch Bio Inc, 2022
- Polycystic Kidney Disease - Pipeline by Healx Ltd, 2022
- Polycystic Kidney Disease - Pipeline by IC-MedTech Inc, 2022
- Polycystic Kidney Disease - Pipeline by Ipsen SA, 2022
- Polycystic Kidney Disease - Pipeline by Johnson & Johnson, 2022
- Polycystic Kidney Disease - Pipeline by Kadmon Holdings Inc, 2022
- Polycystic Kidney Disease - Pipeline by ManRos Therapeutics, 2022
- Polycystic Kidney Disease - Pipeline by Mironid Ltd, 2022
- Polycystic Kidney Disease - Pipeline by Mitotherapeutix LLC, 2022
- Polycystic Kidney Disease - Pipeline by Otsuka Pharmaceutical Co Ltd, 2022
- Polycystic Kidney Disease - Pipeline by Pano Therapeutics Inc, 2022
- Polycystic Kidney Disease - Pipeline by Poxel SA, 2022
- Polycystic Kidney Disease - Pipeline by Reata Pharmaceuticals Inc, 2022
- Polycystic Kidney Disease - Pipeline by Regulus Therapeutics Inc, 2022
- Polycystic Kidney Disease - Pipeline by Shanghai Alebund Pharmaceuticals Ltd, 2022
- Polycystic Kidney Disease - Pipeline by Surrozen Inc, 2022
- Polycystic Kidney Disease - Pipeline by XORTX Therapeutics Inc, 2022
- Polycystic Kidney Disease - Dormant Projects, 2022
- Polycystic Kidney Disease - Dormant Projects, 2022 (Contd..1)
- Polycystic Kidney Disease - Discontinued Products, 2022
List of Figures
- Number of Products under Development for Polycystic Kidney Disease, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AceLink Therapeutics Inc
- Amathus Therapeutics Inc
- AmMax Bio Inc
- Angion Biomedica Corp
- ATLAS Molecular Pharma SL
- Bristol-Myers Squibb Co
- Camurus AB
- Centessa Pharmaceuticals Plc
- Chimerna Therapeutics Inc
- Chinook Therapeutics Inc
- DiscoveryBiomed Inc
- Eloxx Pharmaceuticals Inc
- Galapagos NV
- Generian Pharmaceuticals Inc
- GLG Pharma SA
- Goldfinch Bio Inc
- Healx Ltd
- IC-MedTech Inc
- Ipsen SA
- Johnson & Johnson
- Kadmon Holdings Inc
- ManRos Therapeutics
- Mironid Ltd
- Mitotherapeutix LLC
- Otsuka Pharmaceutical Co Ltd
- Pano Therapeutics Inc
- Poxel SA
- Reata Pharmaceuticals Inc
- Regulus Therapeutics Inc
- Shanghai Alebund Pharmaceuticals Ltd
- Surrozen Inc
- XORTX Therapeutics Inc
